This finding compares favorably with a similar population of refractory trastuzumab plus pembrolizumab-treated HER2+ patients with breast cancer who received prior anti-HER2, where no responses were observed in patients with PD-L1− tumors61. Here, ERBB2 is linked to breast carcinoma.